Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SOL-804 vs Zytiga in Healthy Men
NCT06014853Phase 1Completed
- Sponsor
- Bukwang Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SOL-804-F in prostate cancer (PCa) (4 arms), sponsored by Bukwang Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Aug 2023; status: completed.
02
Drugs
SOL-804-F
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06014853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014853.